Vildagliptin is an oral medication prescribed to help adults manage Type 2 Diabetes Mellitus. It serves as an option for controlling high blood sugar (hyperglycemia) when therapeutic efforts, including diet and physical activity, are not sufficient to achieve necessary glucose management targets.

This medication is used in various therapeutic settings:

• As a single-agent therapy when treatments like metformin are unsuitable due to intolerance or contraindications.
• As part of a dual or triple therapy in combination with other anti-diabetic medications, such as a sulfonylurea or insulin (with or without metformin), to further support blood glucose reduction.

The core benefit is assisting the body in maintaining glucose balance throughout the day. Its use is associated with improvements in blood sugar control, which is important for addressing the long-term progression of the condition.

---

Quick Fact: Relief for Inadequate Blood Sugar Control

Regulatory References

1. EMA therapeutic overview for Galvus (Vildagliptin)

Who can and cannot use Vildagliptin?

This section details official population eligibility and exclusion criteria based strictly on regulatory documents from health authorities like the FDA and EMA.

Contraindicated Populations (Must Not Use)

Criteria	Population/Condition
Hypersensitivity	Known allergy to vildagliptin or any excipients.
Diabetes Type	Patients with Type 1 diabetes mellitus.
Acute State	Patients with diabetic ketoacidosis.
Hepatic Function	Patients with hepatic impairment, specifically pre-treatment Alanine Aminotransferase (ALT) or Aspartate Aminotransferase (AST) levels ge 3 times the upper limit of normal (ULN).

Populations with Restricted or Conditional Use

• Renal Impairment: Use is restricted. Patients with moderate or severe renal impairment or End Stage Renal Disease (ESRD) require a lower recommended dose (e.g., 50 mg once daily).
• Heart Failure: Use is not recommended for patients with NYHA functional class IV heart failure due to limited clinical experience.
• Children and Adolescents (under 18 years): Use is not established and the medicine is generally not recommended.

Pregnancy and Lactation

Vildagliptin should not be used during pregnancy or breastfeeding due to a lack of established safety data for these populations.

Interaction scope

Vildagliptin is generally considered to have a low potential for drug-drug interactions because it is primarily eliminated by hydrolysis and is not a substrate, inhibitor, or inducer of Cytochrome P450 (CYP450) enzymes. This metabolic profile indicates that Vildagliptin is unlikely to affect the metabolism of many other commonly co-prescribed medicines.

Clinically Relevant Interactions

Interactions are mainly pharmacodynamic, meaning they relate to the combined effects on the body, rather than changes in drug concentration. These include:

• ACE Inhibitors: Concomitant use with Angiotensin Converting Enzyme (ACE) inhibitors is associated with an increased risk of angioedema (swelling of the face, lips, tongue, or throat) compared to the use of either medicine alone.
• Insulin and Sulfonylureas: When Vildagliptin is used in combination with Insulin or a Sulfonylurea (e.g., glibenclamide/glyburide, glipizide), there is an increased risk of hypoglycemia (low blood sugar). A reduction in the dose of the Sulfonylurea may be necessary to mitigate this risk.

Other Interactions

The blood glucose-lowering effect of Vildagliptin may be reduced by specific classes of active substances. These include certain thiazide diuretics, corticosteroids, thyroid products, and sympathomimetics.

In studies with other commonly used medicines—including metformin, pioglitazone, glibenclamide, amlodipine, digoxin, ramipril, simvastatin, valsartan, and warfarin—no clinically relevant pharmacokinetic interactions were observed.

How Vildagliptin Works: Mechanism of Action

Vildagliptin exerts its action primarily as a selective, competitive, and reversible inhibitor of the enzyme Dipeptidyl Peptidase-4 (DPP-4). This molecular interaction prevents the rapid enzymatic degradation of incretin hormones, specifically Glucagon-like peptide-1 (GLP-1) and Glucose-dependent insulinotropic polypeptide (GIP), resulting in higher circulating plasma concentrations of their active forms.

The preservation of active incretins potentiates their physiological signaling function, establishing a basis for the drug's downstream effects on the pancreas. Acting on pancreatic beta-cells, the mechanism leads to an increase in insulin secretion rate, while simultaneously acting on alpha-cells to decrease the glucagon secretion rate. This regulatory action is crucially glucose-dependent, meaning it is primarily engaged when blood glucose levels are elevated, thereby resulting in targeted changes to the overall glucose homeostasis pathway.

Vildagliptin is an oral antihyperglycemic agent administered solely by mouth as a tablet, adhering to standardized regulatory guidelines for use. The specific total daily dose, which must not exceed the maximum of 100 mg, determines the official frequency pattern. The usual dose is 50 mg or 100 mg daily, taken in the following standardized regimens:

Labeled Dosing and Administration

Use Context	Recommended Vildagliptin Daily Dose	Dosing Frequency
Monotherapy/Combination with Metformin, TZD, or Insulin	100 mg	Administered as 50 mg twice daily (morning and evening).
Dual Combination with Sulfonylurea	50 mg	Administered as a single dose once daily (in the morning).
Moderate/Severe Renal Impairment or ESRD	50 mg	Administered as a single dose once daily.

The tablet can be taken with or without a meal, providing flexibility for administration time. In cases where a dose is missed, official instructions state the tablet should be taken immediately upon remembering, but the total intake must not exceed the 100 mg maximum on that day.

Population-Specific Rules

No dose adjustment is required for older adults (aged 65 years and over). However, the medication is not generally recommended for the pediatric population due to a lack of established data. Furthermore, official labeling restricts its use in patients with compromised hepatic function, specifically those with pre-treatment liver enzyme levels (ALT or AST) elevated above three times the upper limit of normal.

Recent clinical evidence for vildagliptin, a Dipeptidyl Peptidase-4 (DPP-4) inhibitor, continues to reinforce its efficacy and favorable safety profile in the management of Type 2 Diabetes Mellitus (T2DM).

Efficacy and Glycemic Control

Studies confirm vildagliptin's role in improving glycemic control, evidenced by significant reductions in HbA1c levels. A key finding from the five-year VERIFY study highlighted the long-term benefit of an early combination strategy using vildagliptin plus metformin compared to the traditional stepwise approach, demonstrating improved durability of glycemic control in newly diagnosed patients. This supports using vildagliptin as part of initial dual therapy.

Vildagliptin is also effective as an add-on therapy. When combined with insulin, it has been shown to improve HbA1c with a low risk of hypoglycemia (very low blood sugar), a benefit attributed to its unique glucose-dependent mechanism of action. Furthermore, clinical experience supports its use as triple oral therapy (e.g., with metformin and a sulfonylurea) and in various patient populations, including the elderly.

---

Cardiovascular and Heart Failure Safety

Long-term cardiovascular safety remains a critical focus for diabetes medications. Large meta-analyses of pooled data from vildagliptin trials indicate that it is not associated with an increased risk of Major Adverse Cardiovascular Events (MACE), such as non-fatal myocardial infarction, non-fatal stroke, or cardiovascular death, when compared to other anti-diabetic treatments.

For patients with pre-existing heart failure (HF), specifically those with a reduced left ventricular ejection fraction, the VIVIDD trial found that vildagliptin was noninferior to placebo in terms of the change in LVEF over 52 weeks. While some increase in left ventricular volumes was observed, the overall incidence of worsening heart failure events was similar between vildagliptin and placebo groups, suggesting a neutral safety profile concerning heart failure outcomes in this high-risk population. However, given the class-wide considerations for DPP-4 inhibitors in patients with heart failure, careful clinical assessment is maintained.

Common questions about Vildagliptin (FAQ)

Q: What is Vildagliptin?

Vildagliptin is a medication classified as a dipeptidyl peptidase-4 (DPP-4) inhibitor. According to regulatory documents, this type of medicine is used to help control blood sugar levels in adults with type 2 diabetes mellitus. It helps control blood sugar by affecting hormone levels that regulate insulin production, according to regulatory data.

---

Q: Can Vildagliptin be used alone?

Studies and official product information indicate that Vildagliptin can be used as monotherapy (on its own). Official product information indicates it can be used alone in certain situations, such as when initial treatment with diet and exercise is insufficient, and when other common medications are not suitable. It is also commonly used in combination with several other types of antidiabetic agents.

---

Q: Does Vildagliptin cause weight gain?

According to official product information, Vildagliptin is generally considered to be weight neutral. This means that, in clinical studies, it was not typically associated with patients gaining or losing weight. This characteristic may be a consideration compared to some other types of antidiabetic medications.

---

Q: What happens if I forget to take a dose?

If a dose is missed, official product labeling generally instructs patients to take it as soon as they remember, unless it is nearly time for the next scheduled dose. If that is the case, they are advised to skip the missed dose and continue with the regular schedule. Patients are instructed by product labels to avoid taking a double dose to compensate for a forgotten one.

---

Q: Can I stop taking Vildagliptin if my blood sugar is controlled?

Regulatory guidance indicates that treatment with Vildagliptin is usually long-term. Patients should continue taking this medication unless advised otherwise by their prescribing healthcare provider. Discontinuance of the medication without professional guidance may impact the control of blood sugar levels.

How to Store and Dispose of Vildagliptin

To ensure Vildagliptin tablet stability, the medicine must be stored at a temperature not exceeding 30, C and must not be frozen. The product requires protection from moisture and should be kept in the original, tightly closed package as dispensed.

Storage and Protection

Requirement	Official Instruction
Temperature	Store below 30, C. Do not freeze.
Container	Keep in original package and tightly closed.
Child Safety	Keep out of the sight and reach of children.

Disposal

Unused or expired Vildagliptin must be disposed of in accordance with local regulatory requirements. The product must not be thrown into wastewater or household waste due to environmental restrictions, including potential long-lasting harmful effects to aquatic life.